<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Inflammation in Parkinson's disease: causes and consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Collins, Louise M.; Toulouse, André; Nolan, Yvonne M.</td>
</tr>
<tr>
<td><strong>Editor(s)</strong></td>
<td>Dushanova, Juliana</td>
</tr>
<tr>
<td><strong>Publication date</strong></td>
<td>2012-02</td>
</tr>
<tr>
<td><strong>Type of publication</strong></td>
<td>Book chapter</td>
</tr>
<tr>
<td><strong>Link to publisher's version</strong></td>
<td><a href="http://www.intechopen.com/articles/show/title/inflammation-in-parkinson-s-disease-causes-and-consequences">http://www.intechopen.com/articles/show/title/inflammation-in-parkinson-s-disease-causes-and-consequences</a> <a href="http://dx.doi.org/10.5772/18184">http://dx.doi.org/10.5772/18184</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td><a href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</a></td>
</tr>
<tr>
<td><strong>Item downloaded from</strong></td>
<td><a href="http://hdl.handle.net/10468/1618">http://hdl.handle.net/10468/1618</a></td>
</tr>
<tr>
<td><strong>Downloaded on</strong></td>
<td>2019-01-10T19:04:08Z</td>
</tr>
</tbody>
</table>
Inflammation in Parkinson’s Disease: Causes and Consequences

Louise M. Collins, André Toulouse and Yvonne M. Nolan
Department of Anatomy and Neuroscience, University College Cork
Ireland

1. Introduction

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder after Alzheimer’s disease (AD) with a prevalence of 0.5-1% among persons older than 65 years of age (Toulouse & Sullivan, 2008). The incidence increases to 2.6% in persons aged 85 and older, and has a mean age of onset of 55 years. Statistics released in 1990 from a unique global study carried out by the World Health Organisation, suggest that there are approximately 4 million PD patients worldwide. However, despite intensive research, the aetiology of this neurodegenerative disease still remains unclear and despite substantial efforts, a cure remains elusive. This, coupled with the increasing aging demographics, makes the importance of research into PD imperative, and the development of novel drug treatments a primary aim, both for economic and humanitarian purposes. The disease is a chronic, progressive neurodegenerative motor disorder, resulting in the selective loss of dopaminergic (DA) neurons within the substantia nigra (SN) pars compacta (pc) of the midbrain. As the disease progresses there is gradual circuitry degeneration within the nigrostriatal pathway, producing motor, cognitive and psychiatric symptoms (Braak et al., 2003). Lewy bodies are classified as the focal pathological hallmark of PD and their presence is necessary for the post-mortem diagnosis of the disease. They are not unique to PD however and are also found in other diseases such as dementia with Lewy Bodies and diffuse Lewy Body disease (Braak et al., 2003). PD can be further characterised by the presence of an accumulation of activated microglia within the SNpc (McGeer et al., 1988).

PD exists in many forms and can be classified into both familial and idiopathic (also referred to as sporadic) forms, with epidemiological studies indicating approximately 5-10% of cases as being familial, and 90-95% as idiopathic (Tomiyama et al., 2008). Familial PD can be transmitted in an autosomal dominant (AD-PD) or recessive fashion (AR-PD). The study of genetic forms of PD has led to a better understanding of the underlying molecular mechanisms occurring during the disease progression. To date, six genes (SNCA, LRRK2, PRKN, DJ-1, PINK1 and ATP13A2) have been implicated in familial forms of PD (Bekris et al., 2010). In contrast to idiopathic PD, the genetic forms of this disease display a significantly younger age of onset and a shorter disease duration (Pankratz & Foroud, 2007). Despite this, patients with the autosomal dominant form of the disease have similar clinical and pathological features to those with idiopathic PD. In idiopathic PD, environmental factors such as toxins, free radicals and inflammation have been considered the most likely
candidates as causative agents. For example, pesticides can induce oxidative stress (an increased production of activated oxygen species such as superoxide anions and hydroxyl radicals) which leads to lipid peroxidation, DNA damage and mitochondrial dysfunction (Dick, 2006; Jenner, 2003). Moreover, there is evidence to suggest that the oxidative stress that occurs at a basal level in the SNpc is increased during PD (Jenner, 2003). The involvement of inflammation in the progression of PD has been well documented and is generally typified by an accumulation of activated microglia in damaged regions of the brain (Gao & Hong, 2008; Long-Smith et al., 2009). Initial evidence stems from a post-mortem study over twenty years ago, which demonstrated the presence of activated microglia and T-lymphocytes in the SNpc of a PD patient (McGeer et al., 1988). Since then, an abundance of studies have supported a role for neuroinflammation and activated microglia in the pathology of PD (Banati et al., 1998; Hirsch & Hunot, 2009; Imamura et al., 2003; McGeer & McGeer, 2004; Orr et al., 2002). Activated microglia are predominantly found in the SNpc in the vicinity of degenerating DA neurons in post-mortem PD brains, but have also been detected in the hippocampus, transentorhinal cortex, cingulate cortex and temporal cortex, where neuronal loss is also prevalent (Banati et al., 1998; Imamura et al., 2003; McGeer et al., 1988; Sawada et al., 2006). The presence of activated microglia in rat brains lesioned with 6-hydroxydopamine (6-OHDA), a neurotoxin used to model PD, has been reported by numerous groups (Akiyama & McGeer, 1989; Crotty et al., 2008; Depino et al., 2003; He et al., 2001). Further evidence implicating inflammation in PD comes from studies that report an increase in the expression of the pro-inflammatory cytokines, interleukin (IL)-1β, tumour necrosis factor-α (TNF-α) and IL-6 in PD patients compared with healthy subjects (Boka et al., 1994; Dobbs et al., 1999; Mogi et al., 1994a; Mogi et al., 1994b). Enzymes associated with inflammation, such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), have also been identified post-mortem in PD brains (Hunot et al., 1996; Knott et al., 2000).

2. Neuroinflammation in Parkinson’s disease

2.1 Microglia

Microglia are the resident immune-competent cells of the central nervous system (CNS). They monitor the brain for invading pathogens and immune insults and are capable of stimulating an adaptive immune response (Garden & Moller, 2006). Pio del Rio-Hortega first ignited interest in microglia in the early 20th century when he identified them as a separate glial entity (del Rio Hortega, 1932), providing a complete and comprehensive framework of their involvement in brain pathology (Raivich et al., 1999). There are currently two proposed subsets of microglia residing within the CNS. There are the “resting” microglia found ramified throughout the brain parenchyma and mostly a permanent population, and the perivascular microglia, which are periodically replaced by bone-marrow derived elements and are strategically located in the basal lamina of brain capillaries and the choroid plexus (Santambrogio et al., 2001). These two subsets differ in their expression of leucocyte common antigen, CD45, which is high (CD45<sub>high</sub>) in perivascular and low (CD45<sub>low</sub>) in parenchymal microglia (Sedgwick et al., 1991). The production of microglia is complex. There is an initial production of microglia during development, a constant turnover of microglia during adulthood and throughout senescence, and an up-regulated production of microglia in response to pathological conditions. Furthermore, each of these stages is likely to be governed by diverse
mechanisms. The origin of microglia remains contentious, but the majority of the neuroscience community support the premise that they are derived from mesodermal precursor cells of hematopoietic lineage (Barron, 1995; Cuadros & Navascues, 1998) due to their expression of macrophage antigens, such as F4/80, Fc receptor (FcR) and macrophage-1 antigen (MAC-1) (Carson et al., 1998). Mesodermal precursor cells infiltrate the brain during embryonic and early postnatal phases of development and have the potential to differentiate into macrophages, dendritic cells (DCs) and granulocytes (Santambrogio et al., 2001). Factors which govern and propel this invasion are not widely understood but are believed to involve cell surface bound molecules and components of the extracellular matrix (Cuadros & Navascues, 1998). As with the origin of microglia, the mechanism of microglial renewal in situ remains controversial. This prolonged controversy to unequivocally differentiate activated endogenous microglia from those of infiltrating blood monocytes is due to a lack of distinguishable cell surface or enzymatic markers (Ransohoff & Cardona, 2010). In addition, the prevailing technique of lethally irradiated chimeras to examine this appears to be fraught with confounding factors. Ajami et al., (2007) utilised chimeric animals obtained through parabiosis, which does not require experimental manipulation, and found that microglial homeostasis is maintained independently of bone-marrow derived precursors. They also reported that mature resident microglia are capable of focal self-renewal and microgliosis in response to insult or injury (Ajami et al., 2007).

Within the healthy adult brain microglia reside as a ubiquitously distributed quiescent cell population, representing 10-20% of non-neuronal cells within the CNS parenchyma. They are functionally related to peripheral tissue macrophages and other cells of the monocyte lineage, but differ in their down-regulated expression of a number of cytoplasmic molecules (Perry, 1998). Historically referred to as “resting” microglia, which discriminates them morphologically from their active amoeboid form found during insult to the CNS, they are characterised by a small rod-shaped somata and numerous elongated, highly ramified processes. Through their protrusions, they are in direct contact with astrocytes, neuronal cell bodies and blood vessels, suggesting that they dynamically interact with a variety of neural elements (Nimmerjahn et al., 2005). As immune effector cells of the CNS, they are extremely receptive to subtle change in their microenvironment, rapidly undergoing morphological as well as functional transformations (Ladeby et al., 2005). Although research in recent years has greatly advanced our knowledge of activated microglia, little has been established concerning the function of the microglia residing in the unperturbed CNS. This is due in part to the exceedingly complex predicament many have faced while trying to culture “resting” microglia in vitro. The removal and dissociation of cells from CNS tissue, either by mechanical or proteolytic means inevitably leads to some level of activation (Garden & Moller, 2006). Many have observed microglial cells in vitro exhibiting an amoeboid morphology in a non-pathogenic environment. Eder and co-workers exposed murine microglia to astrocyte-conditioned medium and noted a dramatic transformation in morphology from a “resting” ramified appearance to “active” amoeboid microglia, within a few hours of treatment. As well as this, they observed a down-regulation in macrophage surface molecules such as major-histocompatibility complex (MHC) class-II, and the adhesion molecules leucocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) (Eder et al., 1999). Well-established histological approaches have allowed “resting” microglia to be examined in situ, capturing them in a “freeze-frame picture” at the time of being placed in fixative but this approach also has limitations and
Advances in multi-photon *in vivo* microscopy however, have shed some light on the function of “resting” microglia *in situ*. By examining the behaviours of eGFP-expressing parenchymal microglia in heterozygous Cx3CR1-mice, it was revealed that microglial processes are incessantly palpating their microenvironment. The protrusions extend and retract rapidly and dynamically, reaching up to several micrometres in length over intervals of seconds to minutes (Davalos et al., 2005; Nimmerjahn et al., 2005). It was postulated that their high motility serves as a “housekeeping” function allowing them to effectively manage the brain milieu and to clear the parenchyma of accumulated metabolic products and deteriorated tissue components (Nimmerjahn et al., 2005). Indeed it has been estimated that they are capable of probing the entire volume of the brain every 4-5 hours. The highly ramified form of microglia covers 30-40μm in diameter and though their processes are in close proximity, they are not in direct contact, suggesting that each cell occupies its own exclusive patrol territory (McGeer & McGeer, 2007; Raivich et al., 1999). As such, they are now more appropriately termed “surveillant” microglia to properly describe their rapid and continuous monitoring of the surrounding vicinity (Ransohoff & Cardona, 2010).

“Surveillant” ramified microglia respond to activating stimuli with a rapid morphological transformation into “active” amoeboid microglia (Nakajima & Kohsaka, 2001). Activated microglia are found in the brain under almost all pathological conditions and are involved in tissue repair, amplification of inflammatory effects, neuronal degeneration and the phagocytosis of dead cells and cellular debris (Davalos et al., 2005). Microglia express a perplexing array of cell surface receptors such as complement receptor 3 and MHC class I and II, whose up-regulation is concomitant with activation of microglia (Nakajima & Kohsaka, 2001). These receptors play a pivotal role in enabling microglia to detect subtle changes in their microenvironment, triggering them to extend their processes to the surrounding area of insult, and to engulf damaged cells via phagocytosis (Davalos et al., 2005). In addition, microglia are considered the main antigen presenting cell (APC) population within the CNS, as both *in vivo* and *in vitro* studies have demonstrated their capacity for antigen presentation in response to a variety of CNS pathological conditions (Graeber & Streit, 2010). Activation of microglia and the consequent up-regulation of MHC class II, CD40 and ICAM-1 stimulate T cell proliferation and the production of IL-2, IFNγ and IL-4. However, the ability of endogenous microglia to act as APCs has been brought into question, with many postulating that it may be the role of perivascular macrophages or invading DCs (Perry, 1998). Today, growing evidence suggests that DCs do in fact participate in the regulation of T-cell responses (Teo & Wong, 2010). Microglia in common with other cells of the myeloid lineage also have the ability to secrete immunomodulatory molecules such as cytokines, chemokines, neurotrophins, reactive oxygen and nitrogen species, which communicate signals to surrounding cells to regulate the innate immune response (Garden & Moller, 2006). Cytokines, such as ILs, IFNs and TNFα/β are low-molecular weight proteins that are usually classified as pro- or anti-inflammatory, and microglia express receptors for these cytokines in an autocrine feedback loop that is critical for down-regulating inflammation and restoration of homeostasis. In the brain, it has been reported that cytokines function in growth promotion, inhibition and proliferation of astrocytes and oligodendrocytes (Hanisch, 2002), modulation of neurotransmitter release (Zalcman et al., 1994) long-term potentiation (Nolan et al., 2005) behavioural impairments such as memory impairment (Yirmiya et al., 2002) anhedonia (Konsman et al., 2002) and anxiety (Anisman & Merali, 1999).
2.2 Activated microglia in Parkinson’s disease

The first evidence for a role of inflammation in PD came from McGeer and colleagues who observed activated microglia and T cells in the post-mortem SNpc of a PD patient (McGeer et al., 1988). We now know from a multitude of studies that microglial activation and consequent neuroinflammatory processes play a role in PD (Hirsch & Hunot, 2009). Whereas mild activation of microglia has apparent beneficial effects, chronic microglial activation in response to neuronal damage, as is evident in PD, results in the death of otherwise viable cells. Activation of microglia either directly via a toxin, pathogen or endogenous protein or indirectly from dying neurons may be both long-lived and self-propelling due to positive feedback from degenerating neurons even after the initial insult has ceased (Gao & Hong, 2008). This repetitive cycle of neurotoxic activation of microglia in response to neuronal damage is referred to as reactive microgliosis (Block et al., 2007) and is a feature of several brain pathologies (Carson et al., 1998). DA neurons in the SNpc are particularly susceptible to microglial-mediated neurotoxicity due to the high densities of microglia present (Kim et al., 2000). Thus, microglial activation and hence neuroinflammation, may be propagated and potentially amplify the destruction of neurons in PD (Gao & Hong, 2008). Substances which are produced by dying DA neurons and can activate microglia include α-synuclein-aggregates (Zhang et al., 2005), neuromelanin (Wilms et al., 2003), adenosine triphosphate (ATP) (Davalos et al., 2005) and matrix metalloproteinase-3 (MMP-3) (Kim et al., 2007; Kim et al., 2005).

Aggregated α-synuclein, the major constituent of Lewy bodies in PD, has been reported to be surrounded by activated microglia or inflammatory mediators (McGeer et al., 1988; Yamada et al., 1992). It has also been shown to activate microglia in primary mesencephalic cultures, which in turn amplify α-synuclein-mediated neurotoxicity (Zhang et al., 2005). The phagocytosis of extracellular aggregated α-synuclein and activation of NADPH-oxidase is essential to further activate microglia and propel DA neurodegeneration (Zhang et al., 2005). Neuromelanin, a neuro-pigment released from stressed DA neurons has been shown to induce microglial activation (Wilms et al., 2003) through proteasomal inhibition (Kim et al., 2006). Its accumulation in human SNpc correlates with age progression, and extra neural melanin has been found in close proximity to activated microglial cells in patients suffering from juvenile idiopathic and methyl-4-phenyl-2,3-dihydropyridine (MPTP)-induced Parkinsonism (Wilms et al., 2007). Supplementation of microglial cultures with human neuromelanin in vitro has been shown to induce chemotactic effects and stimulate the release of TNFα, IL-6 and NO (Wilms et al., 2003). Thus, the release of neuromelanin can augment microglial activation and contribute to a self-perpetuating cycle of neuronal degeneration and chronic inflammation (Kim et al., 2006). Extracellular ATP, a purinergic neurotransmitter, was initially described as an activator of microglial cells in 1993 (Kettenmann et al., 1993). The effects of ATP released from damaged neurons are mediated through its signalling with purinergic receptors, namely the metabotropic G-protein coupled P2Y receptors and the ligand gated ionotropic P2X receptors, both of which are expressed on microglia (Butt, 2011). Upon stimulation, activated microglia migrate along a chemotactic gradient to the site of injury or inflammation, facilitated by the release of pro-migratory factors such as extracellular ATP, UTP and members of the chemokine family from damaged cells. ATP then interacts with P2 receptors on microglia to stimulate the release of TNFα, IL-1β, iNOS and NO. Experiments by Kim et al have identified a pivotal role for the protease MMP-3 in DA neuronal activity (Kim et al., 2005). MPP⁺-stressed primary mesencephalic DA neurons induce and release active MMP-3, which is toxic to DA
neurons. It has been reported that primary microglial cultures treated with catalytically active recombinant MMP-3 stimulated microglial activation, superoxide generation and enhanced DA neuronal cell death while MPTP-treated MMP-3−/− mice attenuated microglial activation, superoxide generation and DA degeneration (Kim et al., 2007). Stimulation with the glycolipid endotoxin lipopolysaccharide (LPS) is currently one of the most common methods for activating microglia in vitro. LPS interacts with Toll-like receptor (TLR) 4, one of a family of pathogen recognition receptors (PRRs) responsive to microbial signals. Microglia have been reported to express 9 of the 12 TLRs (Jack et al., 2005). LPS-stimulated microglia release inflammatory cytokines (IL-1β, IL-1 receptor antagonist (IL-1RA), IL-6, IL-8, IL-10, IL-12, IL-18, macrophage colony stimulating factor), chemokines (macrophage inflammatory protein (MIP)-1α, MIP-1β, TNF-α, TNF-β, monocyte chemoattractant protein-1 (MCP-1), RANTES), and prostaglandins (Kim & de Vellis, 2005; Nakamura, 2002), as well as stimulating an increase in myristoylated alanine-rich C kinase substrate (MARCKS), MARCKS-related protein, protein kinase-Ç, iNOS and NO production (Garden & Moller, 2006). Cytokines produced by LPS-stimulated microglia can potentiate microglial activation through autocrine signalling to create a self-propagating cycle of expression. Pro-inflammatory cytokines IL-1β, TNFα, IL-2 and IL-6 are constitutively expressed at basal levels in PD patients as evidenced in post-mortem, serum and cerebrospinal fluid in vivo (Boka et al., 1994; Dobbs et al., 1999; Mogi et al., 1994a; Mogi et al., 1994b; Stypula et al., 1996). Moreover, the death signalling receptor TNF receptor type-1 (TNFR-1) is expressed on DA neurons in human SNpc (Boka et al., 1994; Mogi et al., 2000). Animal studies support an involvement of pro-inflammatory cytokines in the DA neuronal degeneration evident in PD. For example, induction of chronic expression of IL-1β in adult rat SNpc using a recombinant adenovirus resulted in DA neuronal cell death after three weeks (Ferrari et al., 2006). Another study using neutralising antibodies to IL-1β and TNF-α showed that approximately 50% of LPS-induced DA neuronal cell death in primary cultures of rat midbrain was mediated by the production of these two cytokines (Gayle et al., 2002).

It has been postulated that microglia are maintained in a quiescent state by numerous microenvironmental inhibitory influences, many of which are produced by neurons. Hence, microglial activation during pathological insult may be due to a “switching-off” of these inhibitory neuronal signals (Ransohoff & Cardona, 2010). One such neuron-cell inhibitory signalling mechanism is the direct cell-to-cell interactions between neuronal-CD200 (OX2) and its receptor CD200R, expressed on microglia. The CD200-CD200R interaction is essential for maintaining microglial homeostasis in the unperturbed CNS. A down-regulation of CD200 expression has been observed in neurons exposed to inflammatory conditions, and inhibition of CD200 causes microglial activation (Lyons et al., 2007). Therefore, there is a direct neuronal mechanism for regulating microglial activity, and loss of this interaction during neuronal cell degeneration may stimulate up-regulation of CD200, facilitating microglial activation. Recent evidence has implicated an impairment of CD200-CD200R interaction as a contributing factor in PD neurodegeneration (Wang et al., 2011). Blockade of CD200R selectively and significantly enhanced DA neuronal cell susceptibility to rotenone and iron-induced neurotoxicity in mesencephalic neuron-glia co-cultures. This was coupled with elevated microglial activation and superoxide generation and a decrease in CD200 expression on DA neurons. Microglia have also been shown to receive inhibitory inputs from a neuronal membrane-tethered chemokine CX3CL1, through its receptor CX3CR1. Removal of this inhibition also unleashed microglial activity (Shan et al., 2011). Other inhibitory signals exist between CD22-CD45, CD172A-CD47 and ICAM5-LFA-1 (Ransohoff & Perry, 2009).
3. Systemic inflammation and Parkinson’s disease

It has been proposed that in chronic neurodegenerative diseases like PD, systemic infections and inflammation can exacerbate symptoms and promote neurodegeneration (Perry et al., 2007). A systemic response includes the liver acute phase response and the behavioural and metabolic components that induce sickness behaviour (Ferrari & Tarelli, 2011; Perry et al., 2007). Specifically, peripheral monocytes, macrophages and Kupffer cells express TLRs and PPRs, which innately recognise specific pathogen-associated molecular patterns (PAMPs) associated with invading pathogens (Dantzer, 2009). A prototypical PAMP, LPS, is specifically recognised by TLR4, which results in the production of pro-inflammatory cytokines IL-1α, IL-1β. Through autocrine signalling these cytokines induce self-synthesis and the synthesis of further cytokines (Dantzer, 2009) inducing general inflammation. Compromise of the blood-brain barrier (BBB) which is observed in neurological disorders, stimulates peripheral leucocytes and systemic inflammatory mediators such as cytokines, to migrate into the brain parenchyma where they induce the activation of microglia and the subsequent release of more cytokines (Ferrari & Tarelli, 2011). For example, peripheral TNFα can stimulate microglia to secrete chronically elevated pro-inflammatory mediators, which in turn can induce chronic self-perpetuating neuroinflammation, resulting in a slow and progressive loss of DA neurons in the SNpc (Qin et al., 2007). The brain recognises cytokines as molecular signals of sickness and induces symptoms of malaise, lassitude, fatigue, anhedonia, apathy, numbness, coldness, and reduced appetite and body temperature (Dantzer, 2009; Perry et al., 2007). To reinforce this theory, it has been demonstrated that a systemic inflammatory challenge in an animal with chronic neurodegeneration exhibits exaggerated brain inflammation, sickness behaviour and an increase in acute neurodegeneration (Perry et al., 2007). This emerging “two-hit hypothesis” in the aetiology of neurodegenerative diseases such as PD, suggests that the disease is multifactorial and a consequence of “multiple-hits” involving diverse inflammatory stimuli (Di Monte, 2003). Infectious agents may comprise the first “hit”, therefore sensitising the brain to subsequent “hits”, which may not have been pathogenic in the absence of an already “primed” system (Jang et al., 2009a). In this instance, microglia in the aged or diseased brain are said to be “primed” and can evoke an exaggerated response contributing to disease progression (Perry et al., 2007).

Clinical and epidemiological reports suggest a correlation between systemic inflammatory events, chronic neuroinflammation and the aetiology and progressive nature of PD (Ferrari & Tarelli, 2011; Long-Smith et al., 2009; Perry, 2010). Postulated risk factors implicated in idiopathic PD include age, genetic predisposition, bacterial or viral infections, neuronal injury such as traumatic brain injury or stroke, and environmental toxins (Koprich et al., 2008; Tansey & Goldberg, 2010). Associations were first established towards the end of the first world war (1924-1918) when the H1N1 influenza-A pandemic was coupled with a dramatic increase in post-encephalitic Parkinsonism (PEP) (also referred to as “sleeping sickness” or von Economo encephalitis) (Jang et al., 2009a; Rail et al., 1981; Tansey et al., 2007). People born during this time were at a 2-3 fold increased risk of developing PD, with PEP implicated in 50% of all Parkinsonism cases (Jang et al., 2009a; Tansey et al., 2007). PEP shares cardinal symptomatology with idiopathic PD including rigidity and bradykinesia but a lack of Lewy body formation (Jang et al., 2009a). Moreover, Takahashi et al., 1995 demonstrated that the H1N1 virus preferentially targets the SNpc, the primary site of pathology in PD (Takahashi et al., 1995). It has also been shown that exposure to the highly
Mechanisms in Parkinson’s Disease – Models and Treatments

Pathogenic neurotropic H5N1 influenza virus increases susceptibility to developing PD with an observed onset of post-influenzal encephalopathies (Jang et al., 2009b). Other viruses associated with secondary Parkinsonism include coxsackie virus (Poser et al., 1969; Walters, 1960), Japanese encephalitis B (Ogata et al., 1997), St. Louis virus (Pranzatelli et al., 1994), west Nile virus (Robinson et al., 2003) and HIV (Tse et al., 2004). Infection with Japanese-encephalitis virus (JEV), which occurs predominantly in India, China and Southeast Asia, for a prolonged period is likely to induce PEP (Ogata et al., 2000; Shoji et al., 1993; Tansey et al., 2007). People with JEV have similar neuropathological and locomotor symptoms to patients with idiopathic PD (Tansey et al., 2007), and the virus has previously been used to create a pre-clinical model of PD in rats (Ogata et al., 1997). This group demonstrated that in Fisher rats infected with JEV, there was marked gliosis and DA neuronal loss in the SNpc similar to that seen in PD, and bradykinesia which could be reversed with L-DOPA and monoamine oxidase (MAO) inhibitors. More recently, in a cohort of 60 JEV patients, transient-type Parkinsonian features were observed in 16 patients, with 19 displaying Parkinsonism with additional dystonia (Misra & Kalita, 2010).

Oxidative stress, through the generation of reactive oxygen species (ROS) is a key regulator of the neuroinflammatory process, with the underlying purpose of removing the cause of inflammation. Progressive neurodegenerative diseases like PD however, are associated with an overproduction of ROS causing neuronal oxidative damage as well as microglial activation, which subsequently leads to the generation of more ROS (Block & Hong, 2005). Moreover, oxidative stress preferentially affects DA neurons in the SNpc, which are particularly vulnerable as they operate under high oxidant conditions due to reduced levels of the anti-oxidant glutathione (Misra & Kalita, 2010; Sian et al., 1994). Accordingly, it has been postulated that pre-exposure to environmental toxins such as heavy metals, organophosphate compounds, neurotoxins, and pesticides like paraquat and rotenone which can induce oxidative stress and the generation of free radicals, increases the susceptibility to the development of PD in later life (Calne & Langston, 1983; Jang et al., 2009a). Pathological and clinical evidence has also identified the involvement of the gastrointestinal tract in enhancing susceptibility to idiopathic Parkinsonism, with Helicobacter pylori infection proposed as a potential trigger in disease progression (Tansey & Goldberg, 2010; Weller et al., 2005). Indeed, polymorphisms in the nucleotide-binding oligomerisation domain 2 (NOD2) gene associated with Crohn’s disease, a chronic inflammatory bowel disease, have been shown to be over-represented in patients with idiopathic PD (Bialecka et al., 2007).

Evidence now suggests that a disruption in neurovascular homeostasis with increased BBB permeability due to factors secreted by activated glia is associated with neuroinflammation in age-related neurodegenerative diseases. Activated glia have an up-regulated expression of cellular adhesion molecules and the subsequent induction of chemokine gradients direct peripheral leucocytes to the site of inflammation (Chung et al., 2010; Stone et al., 2009). Indeed, positron emission tomography (PET) and histological studies of PD patients as well as MPTP and LPS-induced models of PD reveal a pathogenic link between neuroinflammation, increased BBB permeability and the consequent infiltration of systemic inflammatory molecules, and DA neuronal death (Chung et al., 2010). PD patients have a reported dysfunction in the BBB transporter system (Kortekaas et al., 2005) and blood vessels in the midbrain (Faucheux et al., 1999). Increased levels of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor have been demonstrated in PD patients and in the MPTP model (Yasuda et al., 2007). A report from a study using
animals provides evidence that nigral injection of VEGF to mice disrupted the BBB permeability and induced DA neuronal death in the ventral mesencephalon (VM) (X. Chen et al., 2008). In another study, systemic injection of high concentrations of LPS to rats caused functional breakdown of the BBB resulting in granulocyte infiltration and activation of parenchymal microglia. The subsequent infiltration of immune cells contributed to the degeneration of DA neurons in the SNpc (Brochard et al., 2009).

Assessment of serum obtained from PD subjects corroborates the involvement of systemic inflammation in PD (Hirsch & Hunot, 2009). Increased levels of CD4+ have been reported in the serum of patients with PD, suggesting peripheral activation of lymphocytes (Bas et al., 2001; Fiszer et al., 1994; Hirsch & Hunot, 2009). Infiltrating cytotoxic CD4+ and CD8+ T cells, but not B cells, have been observed in the inflamed SNpc of post-mortem PD human specimens and in the MPTP-induced mouse model of PD during the course of neurodegeneration (Brochard et al., 2009; Ferrari & Tarelli, 2011; Stone et al., 2009). In support of a role for systemic immune cells in the degeneration of nigral DA neurons, CD4/- mice have been shown to be resistant to MPTP-induced neurotoxicity in the SN (Brochard et al., 2009). Amplified TNFα, IL-2, IL-6 and RANTES (Brodacki et al., 2008; Dobbs et al., 1999; Rentzos et al., 2007; Stypula et al., 1996) levels have also been detected in serum obtained from PD patients. Increases in serum cytokines may serve as a therapeutic marker for PD as a blood sample study of men with high plasma concentrations of IL-6 revealed an increased risk of developing PD (H. Chen et al., 2008). In a cohort of 46 PD patients, increased serum levels of soluble TNFR-1, which modulates TNFα activity were detected, which is in agreement with studies showing elevated TNFR-1 in the SNpc of PD brains (Mogi et al., 2000), although this was not associated with clinical parameters. Another group however, has demonstrated that LPS-induced increase of MCP-1, RANTES, MIP-1α, IL-8, IL-6 and IFNγ levels secreted by peripheral blood mononuclear cells significantly correlated with the severity of PD symptoms (Reale et al., 2009). Systemic low level of inflammation induced by a non-toxic dose of LPS has been shown to increase the severity of nigral DA neuronal cell loss in response to a subsequent low-dose of 6-OHDA in the rat model of PD (Koprich et al., 2008), while chronic systemic IL-1β also exacerbated neurodegeneration and microglial activation in the SN of 6-OHDA-treated rats (Pott Godoy et al., 2008). These data support the role of primed microglia, in the “two-hit hypothesis”.

Evidence now suggests that prenatal infections may be a risk factor for the development of PD in later life. Brains from postnatal day (P) 21 rat pups born to dams that were intraperitoneally injected with LPS at the gestation window of vulnerability (embryonic day (E) 10.5), displayed reduced numbers of tyrosine hydroxylase (TH) immunoreactive cells in the SN and ventral tegmental area. This apparent DA neuronal loss was associated with reduced striatal dopamine and an increase in TNFα in the striatum and mesencephalon. The loss of TH+ cells was still observed 33 days post-injection (Ling et al., 2002). It has thus been suggested that prenatal infections such as bacterial vaginosis (BV) in humans may be potential risk factors for PD. Indeed, during pregnancy, levels of LPS and TNFα are elevated in the chorioamniotic environment of women with BV, which may hinder typical DA neuron development (Ling et al., 2002). One group has reported loss of DA neurons up to 16 months post prenatal exposure of rats to LPS, which corresponds to the mean age in humans at which PD symptoms are first observed. Thus, prenatal exposure of rats to LPS has been suggested as a potential model of PD as it induces a slow, protracted loss of nigral DA neurons (Carvey et al., 2003). Further validation for this model was demonstrated by
significant dopamine and serotonin reductions observed in the frontal cortex, nucleus accumbens, striatum, amygdala, hippocampus and hypothalamus, comparable to the neurochemical alterations evident in PD subjects (Wang et al., 2009). In a study to examine the effect of systemic inflammation on the progression of PD, prenatally LPS-exposed rats were subjected to a moderate dose of 6-OHDA at four-months. The data revealed that both prenatal LPS exposure and postnatal 6-OHDA-treatment produced significant DA neuron loss. However, the combined effect was additive and not synergistic. This may have been due to the young age of the animal or the toxin used (Ling et al., 2004). This model was subsequently investigated but with prenatally LPS-exposed rats treated with rotenone rather than 6-OHDA postnatally. The combined effects of LPS and rotenone produced a synergistic TH+ cell loss in the SN relative to controls, which was associated with increased striatal-dopamine activity, TNFα and increased reactive microglia (Ling et al., 2004).

4. Inflammation in animal models of Parkinson's disease

4.1 MPTP model

The MPTP model of PD has been extensively used to elucidate the basal ganglia response to nigrostriatal deficits as well as to examine the validity of novel drug treatments for PD. The MPTP neurotoxin was initially discovered during the 1980s in humans intoxicated with a by-product of an illicit drug synthesis scheme who presented with symptoms manifesting as severe Parkinsonism (Langston et al., 1983; Langston & Ballard, 1983). Post-mortem analysis, ranging between 3-16 years post-MPTP administration, revealed selective DA neurodegeneration and gliosis, with microglial clustering occurring around nerve cells (Langston et al., 1999). It was subsequently postulated that activated microglia might perpetuate DA neuronal degeneration after a primary insult of environmental or genetic origin (Hirsch et al., 2003). Currently, MPTP administration is the most universally used agent for reproducing PD pathologies. It is primarily used in murine and non-human primate models of PD but less frequently in rats, as rat DA neurons are elusively resistant to MPTP-toxicity and are incapable of recapitulating analogous symptoms (Przedborski & Vila, 2003). Motor-impairment symptoms of PD such as bradykinesia, tremor at rest, gait disturbances, postural instability and rigidity have all been observed in MPTP-treated primate models (Bove et al., 2005). While MPTP can mimic a wide range of PD-like symptoms it does not manifest one of the pathological hallmarks of PD, namely the formation of Lewy body-like inclusions, nor can it induce sustained motor impairments. MPTP is highly lipophilic and can easily infiltrate the BBB where it is spontaneously oxidised to an active form, 1-methyl-4-phenyl-2,3-dihydropyridium (1-MPP+) by MAO-B in glial cells. 1-MPP+ is released into the extracellular space where it is taken up by DA neurons via the DA transporter (DAT) (Przedborski & Vila, 2003). Here, it accumulates in the mitochondrial complex and is involved in potently inhibiting mitochondrial complex-1 of the electron transfer chain, leading to an increased production of ROS such as O₂⁻ and a decrease in ATP. In addition, 1-MPP+ can bind to vesicular monoamine transporter-2, enabling its translocation into the synaptic vesicles where it stimulates the extrusion of synaptic DA. This excess DA is auto-metabolised resulting in a burst of ROS such as hydrogen peroxide (H₂O₂) and superoxide radicals (O₂⁻). Accumulation of ROS subsequently causes oxidative degradation of DNA, lipids and proteins resulting in the demise of nigral neurons. This MPTP-induced burst of ROS is generated by microglial
NADPH, therefore, activated microglia have been shown to play an essential role in MPTP-induced neurotoxicity (Gao et al., 2003; Wu et al., 2003). Moreover, cytosolic DA oxidation can be catalysed by COX-2, which has been shown to be up-regulated in nigral DA neurons in both MPTP-treated mice, rats and in human post-mortem samples (Teismann & Ferger, 2001; Teismann et al., 2003).

In an effort to examine a potential role for glia in DA neuronal degeneration, focus was initially placed on deciphering the temporal relationship between DA neurodegeneration and glial activation in MPTP-induced PD murine models. Significant depletion of DA fibres and activated astroglia in the striatum was observed 24-48 hours and 48 hours post-MPTP-administration, respectively (O’Callaghan et al., 1990). The duration of astroglia activation was directly dependent on the extent of DA neuronal damage, and was sustained for the duration of MPTP-administration. It was subsequently reported that microglial activation was observed in the striatum 48 hours post-MPTP administration (Francis et al., 1995), while further studies elucidated that activated microglia were present in the SNpc 24 hours post-MPTP and that activation was sustained for 14 days (Czlonkowska et al., 1996; Kohutnicka et al., 1998). Other groups pinpoint microglial activation in the SN of mice as early as 12 hours and peaking at 24 hours post-MPTP-administration (Dehmer et al., 2000; Liberatore et al., 1999). It has since been reported that activated amoeboid microglia have been observed in the SN of monkeys years after systemic MPTP-injection (McGeer et al., 2003). A further study has implicated a role for cytokines and chemokines in the acute MPTP mouse model of PD by demonstrating that real-time PCR detected elevated mRNA expression of TNFα, MCP-1 and IL-1α in the mouse striatum 2-4 hours post-MPTP-administration (Sriram et al., 2006). However, ablation of TNFα or TNFR-1 did not affect chronic MPTP-induced nigral DA neuronal cell degeneration in mice (Ferger et al., 2004; Leng et al., 2005).

4.2 6-OHDA model

6-OHDA is a hydroxylated analogue of DA, which is actively taken up into DA neurons via DAT expressed on the nerve terminals. It is directly toxic to DA neurons and is used to model PD in rodents. However, since it is unable to cross the BBB, it must be stereotaxically injected into the SN, which results in a widespread and almost immediate destruction of DA neurons (Stanic et al., 2003). The standard delivery method of 6-OHDA is unilateral injection into either the VM, the medial forebrain bundle or the striatum, avoiding areas containing noradrenergic neurons as 6-OHDA can be taken up via the noradrenaline transporter (Deumens et al., 2002). Striatal lesions result in destruction of the nigral DA neuronal terminals leading to a dying back mechanism whereby the cell bodies in the SN are affected secondarily and progressively (Kirik et al., 1998; Sauer & Oertel, 1994). This creates a therapeutic window of opportunity whereby potential neuroprotective strategies can be evaluated. Loss of TH⁺-immunoreactive cells are detectable as early as 24 hours post-6-OHDA lesion in the striatum, peaking in the third week post-lesion. However, loss of TH⁺ cells in the SN does not appear until the second week post-lesion (Blandini et al., 2007). Behavioural testing such as drug-induced rotations can then be performed to assess the anti-Parkinsonian abilities of potential therapies. While the 6-OHDA-lesion model remains one of the most popular animal models of PD to date, like the MPTP model, it fails to encapsulate all the hallmarks of PD pathology, particularly a lack of Lewy body formation. Secondly, PD is a chronic disorder potentially lasting 1-2 decades, so the 6-OHDA-model is in fact regarded as an acute model of PD. As in the MPTP-induced animal model of PD,
activated microglia have been observed in the SN and nigrostriatal tract of 6-OHDA-lesioned rats (Akiyama & McGeer, 1989; Depino et al., 2003; He et al., 2001). Microglial activation was initially observed 1-day post 6-OHDA-lesion but appeared transient in nature (Akiyama & McGeer, 1989). We have observed a significant increase in the number of activated microglia, indicated by MHC class II in the SNpc of 6-OHDA-lesioned rats at 10-28 days post lesion (Crotty et al., 2008). Pro-inflammatory cytokines have also been implicated as neurotoxic mediators of 6-OHDA-induced DA neuronal death; blockade of the soluble form of the TNF-α receptor but not the transmembrane form was found to attenuate the death of DA neurons in 6-OHDA-lesioned rats (McCoy et al., 2006). We have previously demonstrated that conditioned-medium (CM) obtained from LPS-stimulated rat glial-enriched cortical cultures can induce loss of DA neurons in primary VM cultures and that this effect can be exacerbated by 6-OHDA treatment. IL-1β released from activated microglia in the CM mediated this effect as blockade of IL-1R1 with IL-1RA attenuated the CM-induced DA neuronal toxicity (Long-Smith et al., 2010).

4.3 LPS model

LPS is one of the main constituents of gram-negative bacteria and is used as a tool to mimic general infection as it is a potent stimulator of immune cells. Intranigral injection of LPS in rats has been shown to manifest Parkinsonism-like symptoms, such as the selective loss of DA neurons in the SN (Arimoto et al., 2006; Castano et al., 1998; Herrera et al., 2000). Thus the LPS model has served as a valuable tool in deciphering the role of glial cells, especially microglia, in the DA neurodegeneration process and has been described by many as the neuroinflammatory model of PD. LPS binds to the serum LPS-binding protein (LBP), which facilitates binding to the CD14 receptor expressed on microglia. The LBP can then dissociate and allow the LPS-CD14 complex to bind to TLR4, resulting in a cascade of intracellular signalling. The adapter protein myeloid differentiation factor 88 (myD88) attaches to TLR4 and interacts with IL-1 receptor-associated kinase (IRAK), which phosphorylates, activating TNF-R-associated factor-6 (TRAF6). The mitogen-activated protein kinases (MAPK) p38 and c-Jun N-terminal kinase (JNK) are activated downstream of this, leading to the up-regulation of transcription factors such as nuclear-factor-κB (NF-κB). This up-regulation results in the production of pro-inflammatory cytokines (McGettrick & O’Neill, 2010). Intranigral injection of LPS in rats has been shown to result in a significant decrease of DA levels in the striatum, microglial activation and a time and LPS-dose-dependent degeneration of DA neurons in the SN (Castano et al., 1998). In this study, microglial activation was observed at 6 hours and peaked at 1-2 days post LPS injection, while DA neuronal degeneration persisted up to at least 21 days after intranigral injection of LPS demonstrating that LPS-induced microglial activation can induce progressive degeneration of nigral DA neurons. Furthermore, it has been reported that prenatal exposure of LPS to rats results in sustained microglial activation and the development of fewer than normal nigral DA neurons (Ling et al., 2006). Systemic administration of LPS has also been found to induce progressive degeneration of nigral DA neurons in rats (Qin et al., 2007). It had previously been suggested that LPS-mediated DA neuronal toxicity required the presence of glia (Bronstein et al., 1995) and indeed a subsequent study reported that a single intranigral injection of LPS induced selective DA neuronal degeneration up to one year post injection (Herrera et al., 2000). Thus, unlike MPTP and 6-OHDA, LPS is not a direct toxin but rather causes indirect death of DA neurons by activating microglia, inducing an inflammatory
reaction and subsequent DA neuronal death. Studies on rat mesencephalic cultures suggest that DA neurons are twice as sensitive to LPS as non-DA neurons and that the toxicity of LPS occurs via microglial activation (Bronstein et al., 1995; Gayle et al., 2002). Although many in vitro studies have supported an involvement of NO in microglial-mediated DA neuronal death after LPS-treatment (Chao et al., 1992; Gibbons & Dragunow, 2006), others have suggested that NO is not involved (Castano et al., 1998; Gayle et al., 2002). The pro-inflammatory cytokines IL-1β and TNF-α are thought to be involved in LPS-mediated toxicity (Gayle et al., 2002). In support of a role for LPS-induced pro-inflammatory cytokines in DA neurotoxicity, we have shown that IL-1β in CM released from LPS-stimulated microglia significantly reduces the percentage of DA neurons in embryonic rat neuronal-enriched cultures that IL-1R1 is expressed on these DA neurons, and that blockade of IL-1R1 prevented the CM-induced DA neuronal death (Long-Smith et al., 2010). Furthermore, blockade of the soluble form of the TNF-α receptor has been reported to reduce microglial activation in the in vivo LPS model of PD (McCoy et al., 2006). Also, Ling and co-workers found that the decreased numbers of nigral DA neurons in rats after prenatal exposure to LPS, was accompanied by elevated levels of TNF-α in the striatum (Ling et al., 2004).

5. Neuroinflammatory diagnostic tools for Parkinson’s disease

Microglial responsiveness to injury and neurodegenerative disease suggests that it may serve as a marker for the diagnosis and progression of disease pathology in PD. There is a current drive to develop non-invasive imaging tools to assess and quantify the dynamics of activated microglia in neurodegenerative diseases like PD. Advances in this technology, especially for identification of microglial biomarkers at the early stages of disease, would have important implications for PD diagnosis, assessment of progression, and therapy. Currently, the best-studied imaging paradigm for microglial activation is the radiolabelled translocator protein (TSPO) ligand using PET (Dolle et al., 2009). This line of research initially started when a correlation was observed between increased binding of Ro5-4864 (a benzodiazepine) and PK11195 (an isoquinoline) to receptors on the surface of mitochondria primarily localised in glial cells (Arlicot et al., 2008; Chauveau et al., 2008). These receptors were originally referred to as peripheral type benzodiazepine receptors and were increased in activated microglia (Park et al., 1996; Stephenson et al., 1995). The nomenclature has since been changed to TSPO as further research elucidated that these receptors are expressed throughout the brain and body (Papadopoulos et al., 2006). Gene-expression analysis in brains of rodents, primates and humans have illustrated that TSPO expression is nearly absent in parenchyma-microglia (Winkeler et al., 2010) but is elevated in many neurodegenerative disorders including, stroke, AD, PD, multiple sclerosis, Huntington’s disease and amyotrophic lateral sclerosis, (Arlicot et al., 2008) thus emphasising the involvement of microglial activation and neuroinflammation in these diseases. TSPOs are the prototypical biomarkers of neuroinflammatory changes in a variety of CNS disorders and have therefore been proposed as potential diagnostic targets for in vivo imaging (Arlicot et al., 2008; Chauveau et al., 2008).

Currently, functional PET and single photon emission tomography (SPECT), in conjunction with ligands for TSPO, can detect microglial activation in vivo. Examples of radiolabelled TSPO ligands include [11C]Ro5-4864 and [11C](R)-PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3 isoquinoline carboxamide) (Chauveau et al., 2008). In PD subjects, PET
imaging revealed microglial activation in the pons, basal ganglia, and frontal and temporal cortical areas. Longitudinal studies of these patients revealed stable $[^{11}C](R)$-PK11195 binding potential (BP; a parameter that mixes receptor density with ligand affinity), indicative of early activation of microglia in PD pathology (Gerhard et al., 2006; Winkeler et al., 2010). However, the $[^{11}C](R)$-PK11195 tracer is limited, as it is incapable of distinguishing between phenotypic differences, and thus possibly functional differences of microglia. To overcome this, a PET tracer for the dopamine-transporter, $[^{11}C]$CFT, has been used in conjunction with $[^{11}C](R)$-PK11195 to examine the viability of the presynaptic DA neurons (Ouchi et al., 2009). This study of 10 drug-naïve PD patients, demonstrated changes in microglial activity in conjunction with DAT density which were investigated using PET imaging with $[^{11}C](R)$-PK11195 and $[^{11}C]$CFT tracers. Subjects underwent magnetic resonance imaging (MRI) prior to PET measurement to define the regions of interest, which would allow for the evaluation of microglial activation in parallel with presynaptic neuronal degeneration in vivo. Elevated midbrain $[^{11}C](R)$-PK11195 BP levels were significantly inversely correlated with $[^{11}C]$CFT BP localised in the putamen. The elevated $[^{11}C](R)$-PK11195 BP also correlated with motor impairment. A follow-up 4-year scan revealed increased microglial activation spread over the extrastriatal region (Ouchi et al., 2009). PET imaging and post-mortem analysis of the brain of a rat lesioned with 6-OHDA revealed reduced $[^{11}C]$CFT BP in the striatum, indicative of DA degeneration, while $[^{11}C](R)$-PK11195 BP was markedly increased in the striatum and SNpc. Post-mortem immunohistochemical analysis corroborated this finding by showing activated microglia in the striatum and SNpc at 4 weeks post-lesion (Cicchetti et al., 2002). Alternative SPECT imaging biomarkers for TSPO such as $[^{123}I]$CLINDE (2-(4′-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide) have been examined in vivo and also pose as potential image-guided diagnostic tools for microglial activation in neurodegenerative diseases like PD (Arlicot et al., 2008).

6. Immunomodulatory therapies

As the wealth of evidence continues to accumulate regarding the role of microglial activation in the pathogenesis of PD, a large number of inhibitory drugs have been investigated. The use of broad spectrum steroidal and non-steroidal anti-inflammatory drugs, specific microglial inhibitors or anti-inflammatory cytokines have not only helped decipher the role of microglial activation in neuroinflammation in PD but also indicated that inhibiting the specific processes involved in microglial activation may be a therapeutic avenue for PD.

The glucocorticoids are well known for their broad range of anti-inflammatory effects and have long been used in clinical settings for the treatment of brain inflammation (Castano et al., 2002). Microglial cells express the glucocorticoid receptor which is involved in the regulation of the transcription factors NF-$\kappa$B and activator protein-1 (AP-1) (Scheinman et al., 1995) which in turn are key regulators of pro-inflammatory cytokine expression (Nadeau & Rivest, 2003). Of particular interest, the synthetic steroid dexamethasone was shown to provide neuroprotection against LPS or MPTP-induced toxicity in rodent models. In both models, the delivery of dexamethasone prevented the activation of microglia usually associated with neurodegeneration (Castano et al., 2002; Kurkowska-Jastrzebska et al., 2004). However, the severe side-effects associated with glucocorticoid use prevent any long-term usage in neuroprotective therapies for PD. Large scale epidemiological studies have shown
that the chronic use of non-steroidal anti-inflammatory drugs (NSAID) such as aspirin or ibuprofen could provide some level of protection against PD (Chen et al., 2005; Chen et al., 2003). Other studies suggest that the role of NSAIDs in decreasing the risk of PD is extremely limited (Hancock et al., 2007; Hernan et al., 2006). A recent meta-analysis of studies published between 1966 and 2008 showed that while NSAIDs as a class do not modify the risk of developing PD, the chronic intake of ibuprofen may have a beneficial effect (Gagne & Power, 2010; Gao et al., 2011; Samii et al., 2009). Ibuprofen possibly mediates this effect via its inhibition of COX activity to inhibit the production of pro-inflammatory lipid mediator prostaglandins (Mitchell et al., 1993). Some of the beneficial effects observed could also be mediated via other mechanisms associated with NSAIDs such as inactivation of the pro-inflammatory nuclear receptor NF-κB (Grilli et al., 1996; Kopp & Ghosh, 1994), activation of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear factor mediating anti-inflammatory effects in microglia (Bernardo et al., 2005) or activation of the Rho kinase pathway (Zhou et al., 2003). Results from animal models of PD demonstrate that aspirin and indomethacin have both been shown to prevent MPTP-induced loss of striatal dopamine in the mouse (Aubin et al., 1998; Kurkowska-Jastrzebska et al., 2002). The NSAID Celecoxib reversed striatal DA neuronal fibre and nigral DA neuronal cell loss in 6-OHDA-treated rats (Sanchez-Pernaute et al., 2004) while aspirin has been shown to prevent 6-OHDA-induced striatal dopamine depletion (Di Matteo et al., 2006).

Other neuroimmunomodulatory strategies include the use of the second generation tetracycline analogue, minocycline. It has been shown to inhibit microglial activation and prevent iNOS and NADPH oxidase generation as well as IL-1β up-regulation (Du et al., 2001). It is a lipophilic molecule which easily crosses the BBB and is reported to have anti-inflammatory and neuroprotective activities (Kim & Suh, 2009). Some studies in experimental models of PD have shown that it is neuroprotective against MPTP-, LPS, or 6-OHDA induced neurodegeneration (Du et al., 2001; He et al., 2001; Tomas-Camardiel et al., 2004; Wu et al., 2002) while others showed that it exacerbated the deleterious effects of MPTP in rodents and non-human primates (Diguet et al., 2004; Yang et al., 2003). While the reason for the discrepancies is unknown, differences between the various studies include doses and timing of intervention and may reflect the dual role of microglia in inflammation. Despite these contradictory results, a phase II randomized double-blind futility clinical trial was set-up. Results after 12 and 18 months suggest that minocycline is well tolerated and does not negatively impact on symptomatic treatment. It is therefore currently recommended for phase III clinical trials to assess its long-term effect on disease progression (NINDS-NET-PD-Investigators, 2006, 2008).

In addition to the role of glial-associated innate immunity, an adaptive immune response may also be involved in triggering cell death in DA neurons. Manipulating this adaptive response mediated by T cells could be a successful approach for neuroprotection. This immuno-intervention aims at redirecting the harmful T cell response towards an anti-inflammatory and protective immune response by means of an antigen-based immunisation. Preclinical results using glatiramer acetate (a random amino acid polymer composed of alanine, glutamine, lysine and tyrosine amino acids) as the immunisation agent showed that this approach could be successful. Glatiramer-acetate primed T cells transferred to MPTP-treated mice were shown to reach the brain where they suppressed microglial activation and provided neuroprotection to the nigrostriatal neurons by inducing the neurotrophic factor glial cell-derived neurotrophic factor (GDNF). Furthermore, specific
depletion of the donor T cells abrogated this neuroprotective effect confirming that the effect is donor T cell dependent (Benner et al., 2004). Interestingly, the donor T cells were shown to secrete high levels of anti-inflammatory cytokines IL-4, IL-10 and TGFβ (Benner et al., 2004). As glatiramer acetate has already been shown to be safe and tolerable in clinical trial and has had significant reduction effects on disability in multiple sclerosis patients (Comi et al., 2011), it represents a very attractive possibility. Interestingly, another neuropeptide, vasoactive intestinal peptide, has been reported to prevent MPTP-induced loss of nigral DA neurons and striatal DA fibres in the mouse while also down-regulating IL-1β and TNF-α expression and iNOS generation (Delgado & Ganea, 2003).

Alternatively, the delivery of anti-inflammatory cytokines such as IL-10 could be considered as an anti-inflammatory therapeutic strategy for PD. Pre-treatment of mesencephalic neuroglial cultures with IL-10 inhibited LPS-stimulated microglial activation and degeneration of DA neurons (Qian et al., 2006). Similar neuroprotective effects were observed in vivo after chronic infusion of IL-10 into the SNpc of rats that were challenged with LPS (Arimoto et al., 2006). More recently, gene therapy approaches have been developed to deliver IL-10 into the rat SNpc, and have proved effective in attenuating the neuronal loss and behavioural deficits in the 6-OHDA rat model of PD (Johnston et al., 2008). Furthermore, the blockade of pro-inflammatory cytokines should be considered as a potential therapeutic avenue. Blocking the soluble TNF signalling by delivery of a dominant-negative form has been shown to promote neuronal survival and reduce the behavioural deficits in the hemi-Parkinsonian rat model of PD (McCoy et al., 2006; McCoy et al., 2008). While these pre-clinical results are interesting, the availability of a broad spectrum of compounds acting on TNF signalling makes this molecule a very attractive target. Etanercept and Infliximab are a new generation of engineered inhibitors of TNF that are broadly used for the treatment of rheumatoid arthritis and other peripheral inflammatory diseases. Their use in CNS diseases is however limited by their general inability to cross the BBB (Tweedie et al., 2007). While direct intrastratal delivery or long-term gene transfer as illustrated above are possibilities, other inhibitors of TNF synthesis may prove useful such as the infamous antiemetic compound thalidomide. Thalidomide is a sedative, immunosuppressive and anti-inflammatory drug that has teratogenic effects (Smithells & Newman, 1992) and inhibits the synthesis of TNF-α (Sampaio et al., 1991). Thalidomide was shown to protect nigrostriatal neurons and prevent striatal DA depletion in the early stages of MPTP-induced neurodegeneration (Boireau et al., 1997; Ferger et al., 2004).

PPARγ has been shown to exert anti-inflammatory functions in both the periphery and the CNS where it is detected in glial and neuronal cells. Following activation by its naturally occurring ligands eicosanoids and prostaglandin J2, it regulates the expression of pro-inflammatory molecules such as iNOS, COX-2 and, indirectly, of broad array of cytokines through its interactions with the transcription factor NF-κB (Chaturvedi & Beal, 2008; Chung et al., 2008). Pioglitazone and rosiglitazone are two synthetic agonists of PPARγ that are approved for the treatment of type II diabetes. In the CNS they exhibit neuroprotective effects in models of neurodegenerative disorders, including PD, by preventing inflammation, oxidative damage and apoptosis (Chaturvedi & Beal, 2008). Specifically, pioglitazone prevents MPTP-induced activation of microglia and DA neuronal cell loss in murine SNpc in vivo (Dehmer et al., 2004). This has been shown to occur through inhibition of MAO-B, the enzyme responsible for conversion of MPTP to its toxic metabolite MPP+ (Quinn et al., 2008). When pioglitazone was administered to rats that were also injected intrastratally with LPS, the resultant LPS-induced microglial activation and DA
Inflammation in Parkinson’s Disease: Causes and Consequences

degeneration was attenuated (Hunter et al., 2007). Recently, the neuroprotective effects of rosiglitazone have been shown in the MPTP mouse model of PD; chronic administration of the drug prevented behavioural deficits, DA neuronal loss and microglial activation in the SNpc in vivo (Schintu et al., 2009).

As mentioned above, NF-κB plays an important role in the regulation of chronic diseases through the promotion of inflammation and of cell survival. Activation of NF-κB requires the activity of the IκB kinase (IKK) complex (Kim et al., 2006). Activated NF-κB has been detected in neurons and activated microglia in the SN of PD patients and MPTP-treated animals suggesting that some of the pro-inflammatory mechanisms regulated by the NF-κB pathways may play an important role in the pathogenesis of PD (Ghosh et al., 2007; Hunot et al., 1997). Recent studies have shown that blockade of NF-κB activity either directly or through IκB can inhibit components of the inflammatory pathways in microglia namely, the oxidative stress pathway and the production of pro-inflammatory cytokines (Anrather et al., 2006; Gauss et al., 2007). Selective inhibition of NF-κB activity by a peptide blocking the IKK complex prevented DA neuronal loss in MPTP-treated mice and suppressed microglial activation (Ghosh et al., 2007). Finally, a selective pharmacological IκB inhibitor has demonstrated neuroprotective properties in LPS- and MPTP-induced models of PD. Treatment with this compound prevented neuronal damage in a process dependant on the presence of microglia. Particularly, it prevented the activation of microglial oxidative pathways and the release of pro-inflammatory cytokines by specific blockade of the NF-κB signalling pathway (Zhang et al., 2010).

7. Conclusion

The death of dopaminergic neurons in the SNpc is the key pathology of PD. Therefore, it is imperative that research is undertaken, not only in areas which could provide protective strategies for the remaining neurons, or which involve dopaminergic neuronal cell replacement therapies, but also into understanding the fundamental mechanisms by which these cells die. Although the precise role of inflammation in the pathogenesis of PD remains unclear, an array of evidence from the clinic and from animal models now points to its substantial involvement in this debilitating disease.

8. Acknowledgment

The authors thank Declan Conroy and Aoife Nolan for technical assistance.

9. References


Inflammation in Parkinson’s Disease: Causes and Consequences


Inflammation in Parkinson's Disease: Causes and Consequences


1314-1318
664-671
141-150
Nolan, Y., Maher, F.O., Martin, D.S., Clarke, R.M., Brady, M.T., Bolton, A.E., Mills, K.H. &
changes in the hippocampus. J Biol Chem, Vol.280, No.10, pp. 9354-9362
astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine. Brain Res, Vol.521, No.1-2, pp. 73-80
No.2, pp. 141-147
S200-204
801-811
Papadopoulos, V., Baraldi, M., Guilarte, T.R., Knudsen, T.B., Lacapere, J.J., Lindemann, P.,
Translocator protein (18kDa): new nomenclature for the peripheral-type
benzodiazepine receptor based on its structure and molecular function. Trends
Pharmacol Sci, Vol.27, No.8, pp. 402-409
benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia,
Vol.16, No.1, pp. 65-70
Perry, V.H. (1998). A revised view of the central nervous system microenvironment and
major histocompatibility complex class II antigen presentation. J Neuroimmunol,
Vol.90, No.2, pp. 113-121
Acta Neuropathol, Vol.120, No.3, pp. 277-286
an acute case due to coxsackie virus type B 2 and re-examination of the etiologic
concepts of postencephalitic parkinsonism. Acta Neurol Scand, Vol.45, No.2, pp. 199-
215


leading to disease progression in Parkinson's disease. *FASEB J*, Vol.19, No.6, pp. 533-542